Trial
NCT05035407
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Kita-kyushu Lung Cancer Antigen 1, Human
Intervention
IL-2 (Aldesleukin)
Why stopped
Site plans to become a site for a multicenter study of this therapy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-02